Tema Etfs LLC Buys 11,035 Shares of Danaher Corporation $DHR

Tema Etfs LLC raised its position in shares of Danaher Corporation (NYSE:DHR) by 211.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,256 shares of the conglomerate’s stock after acquiring an additional 11,035 shares during the period. Tema Etfs LLC’s holdings in Danaher were worth $3,223,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Ceredex Value Advisors LLC increased its holdings in Danaher by 1.6% in the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after purchasing an additional 3,862 shares in the last quarter. Chicago Capital LLC increased its stake in shares of Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares during the period. Weitz Investment Management Inc. increased its stake in shares of Danaher by 6.1% in the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after buying an additional 30,300 shares during the period. Nvwm LLC boosted its position in Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after buying an additional 1,204 shares during the period. Finally, ASR Vermogensbeheer N.V. boosted its position in Danaher by 1.9% during the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after buying an additional 6,136 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.4%

Shares of Danaher stock opened at $238.28 on Monday. The stock’s 50-day moving average is $225.77 and its 200 day moving average is $210.67. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The firm has a market cap of $168.31 billion, a price-to-earnings ratio of 49.13, a PEG ratio of 4.24 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.71 earnings per share. Equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.5%. Danaher’s dividend payout ratio is currently 26.39%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 30,248 shares of company stock worth $6,609,663. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DHR shares. Evercore ISI reaffirmed an “outperform” rating and set a $250.00 price target on shares of Danaher in a research note on Monday, January 5th. Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Wells Fargo & Company lifted their target price on Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Jefferies Financial Group upped their price target on Danaher from $245.00 to $255.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley initiated coverage on Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 price objective for the company. Twenty-one research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $249.92.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.